Frank Kolbinger
Overview
Explore the profile of Frank Kolbinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
781
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Millar N, McInnes I, Kolbinger F, Raulf F, Akbar M, Li Y, et al.
RMD Open
. 2025 Feb;
11(1).
PMID: 39988349
Objectives: Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests blockade of interleukin 17A (IL-17A)...
2.
Tomalin L, Kolbinger F, Suprun M, Wharton Jr K, Hartmann N, Peters T, et al.
Clin Exp Dermatol
. 2024 Jan;
49(8):801-809.
PMID: 38240024
Background: Secukinumab, an anti-interleukin (IL)-17A monoclonal antibody, induces histological and molecular resolution of psoriatic plaques by 12 weeks. However, the long-term effects of secukinumab on the molecular resolution of psoriatic...
3.
Bier K, Senajova Z, Henrion F, Wang Y, Bruno S, Rauld C, et al.
J Invest Dermatol
. 2024 Jan;
144(7):1544-1556.e9.
PMID: 38237730
Atopic dermatitis (AD) is a debilitating inflammatory skin disorder. Biologics targeting the IL-4/IL-13 axis are effective in AD, but there is still a large proportion of patients who do not...
4.
Lebwohl M, Iversen L, Eidsmo L, Krueger J, Suarez-Farinas M, Tomalin L, et al.
Clin Exp Dermatol
. 2023 Oct;
49(8):793-800.
PMID: 37820029
Background: Secukinumab is effective against a range of psoriatic manifestations. Investigating psoriasis (PsO) relapse following secukinumab discontinuation could provide insights into long-term PsO remission. Objectives: To examine PsO relapse rates...
5.
Krueger J, Langley R, Nigen S, Kasparek T, Di Comite G, Ortmann C, et al.
Exp Dermatol
. 2023 Jun;
32(10):1834-1847.
PMID: 37272375
Interleukin (IL)-23-independent IL-17A production has been suggested to be involved in persistent manifestations of psoriatic disease, including anti-IL-12/23-refractory psoriatic plaques; this study aimed to test this hypothesis by investigating the...
6.
Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et al.
J Eur Acad Dermatol Venereol
. 2023 Jan;
37(5):1004-1016.
PMID: 36606536
Background: Biologic treatments have been studied mainly in patients with a long-term history of psoriasis and previous treatment failures. Objectives: The purpose of this primary analysis of the STEPIn study...
7.
Goepfert A, Barske C, Lehmann S, Wirth E, Willemsen J, Gudjonsson J, et al.
Cell Rep
. 2022 Oct;
41(3):111489.
PMID: 36260993
Signaling through innate immune receptors such as the Toll-like receptor (TLR)/interleukin-1 receptor (IL-1R) superfamily proceeds via the assembly of large membrane-proximal complexes or "signalosomes." Although structurally distinct, the IL-17 receptor...
8.
Kimball A, Loesche C, Prens E, Bechara F, Weisman J, Rozenberg I, et al.
Exp Dermatol
. 2022 May;
31(10):1522-1532.
PMID: 35638561
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory, follicular skin disease whose pathology is complex and not fully understood. The objective of this study was to elucidate the role of...
9.
Kolbinger F, Di Padova F, Deodhar A, Hawkes J, Huppertz C, Kuiper T, et al.
Pharmacol Ther
. 2021 Jun;
229:107925.
PMID: 34171337
Psoriasis, psoriatic arthritis, and axial spondyloarthritis are systemic inflammatory diseases, each commonly manifesting as a spectrum of symptoms, complications, and comorbidities that arise differently in individual patients. Drugs targeting inflammatory...
10.
Goepfert A, Lehmann S, Blank J, Kolbinger F, Rondeau J
Immunity
. 2020 Mar;
52(3):499-512.e5.
PMID: 32187518
Interleukin-17A (IL-17A), IL-17F, and IL-17A/F heterodimers are key cytokines of the innate and adaptive immune response. Dysregulation of the IL-17 pathway contributes to immune pathology, and it is therefore important...